Pseudomonas aeruginosa responsible for nosocomial infections prevail in hospitals, producing b-lactamase enzymes that hydrolyze b-lactam drugs and reduce their efficacy. This study was carried out to determine prevalence, susceptibility and production of different b-lactamases by P. aeruginosa. The isolates were screened and characterized using standard protocols. Among isolates 32%, 10%, 6% and 6% were obtained from pus swabs, sputum, urine and body fluids, respectively. Prevalence of MBL positive strains was 25.7%, AmpC was 17.1% and ESBL was 8.5%. The co-production of MBL+AmpC, MBL+ESBL and ESBL+AmpC was 10%, 5.7% and 2.8% respectively. MBL+AmpC positive strains were 100% resistant to ceftriaxone, amoxicillin+clavulanic acid, norfloxacin. ciprofloxacin, cefaperazone+sulbactam, pipracilline+tazobactum, cefotaxime and imipenem, While MBL+ESBL positive stains were 100% resistant to ceftriaxone, amoxicillin+clavulanic acid, norfloxacin, ciprofloxacin, ceftaxime, ceftazidime, imipenem, cefaperazone+sulbactam and pipracilline + tazobactum. Only least resistant (25%) observed for amikacin and cefepime. Co-production of AmpC+ESBL positive strains were 100% resistant to ceftriaxone, amoxcilline+clavulanic acid, ciprofloxacin, norfloxacin and cefotaxime, cepaferazone/sulbactum and pipracilline/tazobactum. Production of MBL was higher than ESBL and AmpC b-lactamase. Co-production of these enzymes was responsible for multidrug resistance. Production of MBL+AmpC was higher than ESBL+AmpC and ESBL+MBL. Least resistance was noted against cefepime and amikacin by MBL, ESBL and AmpC co-producers.